Longitudinal study of symptom distress in breast cancer patients before and one year after surgery
10.3760/cma.j.issn.1674-2907.2020.03.004
- VernacularTitle:乳腺癌患者术前及术后1年期间症状困扰程度的纵向研究
- Author:
Huiting ZHANG
1
;
Xiaoli ZHU
;
Yue JIANG
;
Huiying QIN
Author Information
1. 中山大学肿瘤防治中心乳腺科
- Keywords:
Breast neoplasms;
Symptom distress;
Longitudinal studies
- From:
Chinese Journal of Modern Nursing
2020;26(3):299-305
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the occurrence and change rules of symptom distress in breast cancer patients before and one year after surgery. Methods From June 2016 to July 2016, this study selected 80 breast cancer patients at initial diagnosis by and with surgery in a Class Ⅲ Grade A cancer hospital of Guangzhou as subjects by pathobiology with the method of convenience sampling. The symptom distress was investigated with the M.D.Anderson symptom inventory (MDASI) before, three months, six months and one year after surgery. Results The scores of symptom sub-scale of breast cancer patients before, three months, six months and one year after surgery were (1.23±1.04), (3.20±1.54), (3.09±1.27) and (1.10±0.69) respectively with statistical differences (F=97.70,P < 0.01). The scores of distress sub-scale of breast cancer patients before, three months, six months and one year after surgery were (1.49±1.63), (4.24±2.30), (3.08±1.86) and (0.98±0.89) respectively with statistical differences (F=89.01,P < 0.01). The level of symptom distress of breast cancer patients was the highest three months after surgery and decreased gradually after that, and was lower one year after surgery than that before surgery. Conclusions Breast cancer patients had the mild to moderate levels of symptom distress from preoperation to one year after surgery. The level of symptom distress of patients is the highest three months after surgery and decreases gradually after that, and is lower one year after surgery than that before surgery. Patients are with varying degrees of symptom distress in each period which points out that we should provide targeted management for adverse reactions caused by disease or treatments at different periods.
